Fisher Funds Reduces Intuitive Surgical Holdings

Institutional investor sells over 125,000 shares of medical equipment provider

Apr. 17, 2026 at 8:56am

Got story updates? Submit your updates here. ›

A high-contrast, close-up image of the inner mechanical components and sensors of an Intuitive Surgical robotic arm, conveying the industrial power and precision of the company's medical technology.The intricate inner workings of Intuitive Surgical's robotic surgical systems reflect the company's technological prowess, but also the complex financial and regulatory landscape it navigates.Sunnyvale Today

Fisher Funds Management LTD reduced its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 53.1% during the 4th quarter, according to a recent SEC filing. The institutional investor now owns 110,764 shares of the medical equipment provider's stock, down from 236,015 shares previously.

Why it matters

Intuitive Surgical is a leading manufacturer of robotic surgical systems, and changes in institutional ownership can signal shifts in market sentiment around the company's prospects. This sale by a major investor like Fisher Funds could indicate broader concerns about the stock's valuation or growth trajectory.

The details

According to the SEC filing, Fisher Funds sold 125,251 shares of Intuitive Surgical stock during the fourth quarter. The firm's total holdings in the company are now valued at $63,068,000, making it Intuitive Surgical's 18th largest institutional investor.

  • The share sale occurred during the fourth quarter of 2025.

The players

Fisher Funds Management LTD

An institutional investment firm that has been a major shareholder of Intuitive Surgical.

Intuitive Surgical, Inc.

A medical technology company that manufactures the da Vinci surgical robotic system.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Fisher Funds' Intuitive Surgical holdings could signal broader concerns about the stock's valuation and growth prospects among institutional investors. However, the company remains a leader in the robotic surgery market, and its long-term outlook will depend on factors like adoption of its systems, reimbursement trends, and competition.